Reactions 1680, p325 - 2 Dec 2017
Liver dysfunction and cerebral infarction: 2 case
In a retrospective, observational study of 21 patients, two
patients [ages and sexes not stated] were described who
developed liver dysfunction and cerebral infarction,
respectively during therapy with tolvaptan [route and dosage
not stated]. The patients with chronic kidney disease and
congestive heart failure, received tolvaptan for excess body
fluid. However, one patient developed liver dysfunction while
another patient developed cerebral infarction during therapy
with tolvaptan. Subsequently, tolvaptan was discontinued in
both patients [durations of treatment to reactions onset and
outcomes not stated].
Author comment: "Two cases were not able to continue
use of tolvaptan because of its side effects". "Among 21 study
participants, 2 patients discontinued tolvaptan treatment
during the study periods because of liver dysfunction and
cerebral infarction, respectively."
Katsumata M, et al. Effects of tolvaptan in patients with chronic kidney disease
and chronic heart failure. Clinical and Experimental Nephrology 21: 858-865, No.
5, Oct 2017. Available from: URL: http://doi.org/10.1007/s10157-016-1379-0 -
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved